Company / Operating Cash Flow
GYRE THERAPEUTICS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.0M
FY2025
5-year range
-$83.8M / $10.7M
FY2021-FY2025
Trend
+127.7%
vs FY2024
Sector context
#76 of 216
Health Care
What the data says
At $1M, GYRE THERAPEUTICS, INC.'s operating cash flow ranks #76 of 216 in the Health Care sector. Declined from $11M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of -54.4%.
Declined from $11M to $1M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -54.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#76 of 216 in Health CareTop 35% of 216This company $1.0M Sector average $659.0M
▼
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of -54.4%, indicating a declining trend.
- In FY2025, operating cash flow increased 127.7% year-over-year.
- Ranks #76 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0M | +127.7% |
| FY2024 | -$3.6M | -134.1% |
| FY2023 | $10.7M | +0.0% |
| FY2022 | $10.7M | +112.7% |
| FY2021 | -$83.8M | -92.0% |
| FY2020 | -$43.6M | +0.0% |
| FY2019 | -$43.6M | -118.7% |
| FY2018 | -$19.9M | +0.0% |
| FY2017 | -$19.9M | -7.9% |
| FY2016 | -$18.5M | +3.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026